LexBlog IP

JANUARY 19, 2022

In April 2014 Foro contacted Vita through the generic contact form on Vita’s website to discuss building a deployment wheel for Foro’s laser, which it marketed as a multiconductor cutting tool. On July 29, 2014, the Parties executed a mutual Nondisclosure and Restricted Use Agreement (the “NDA”). Code §§ 134A.001

Patent 52

Patent Designs Design Confidentiality 52

Trading Secrets

JANUARY 19, 2022

In April 2014 Foro contacted Vita through the generic contact form on Vita’s website to discuss building a deployment wheel for Foro’s laser, which it marketed as a multiconductor cutting tool. On July 29, 2014, the Parties executed a mutual Nondisclosure and Restricted Use Agreement (the “NDA”). Code §§ 134A.001

Patent 52

Patent Designs Design Confidentiality 52

Patently-O

SEPTEMBER 13, 2021

Ericsson and HTC entered into three such licensing agreements in 2003, 2008 and 2014. Under the 2014 agreement, HTC paid Ericsson a lump sum of $75 million for a 2-year license to use Ericsson’s 2/3/4G SEPs. However, this case did not sound in patent infringement, but in breach of contract. 2014), Microsoft v.

Licensing 56

Licensing Contracts Patent Law Law 56

Fish & Richardson Trademark & Copyright Thoughts

DECEMBER 2, 2020

The 2018 Farm Bill led to widespread availability of products containing CBD, which are commonly marketed as dietary supplements, drugs, food, and cosmetics. As CBD has not been banned, cosmetic products that contain CBD may be marketed for cleansing, beautifying, promoting attractiveness, or altering the appearance of the human body.

IP 52

IP Registration Trademark Branding 52

The IPKat

SEPTEMBER 23, 2022

This referral adds to the referral made a few months earlier by the Finnish Market Court on the interpretation of Article 3(c) and its interplay with Article 3(a) (case C-119/22 ). According to the search report issued by the EPO in the Belgian grant procedure, the invention as claimed was not patentable due to a lack of novelty.

Litigation 82

Litigation Law Patent Invention 82

Patently-O

JANUARY 3, 2024

Background of the Dispute DexCom and Abbott are competitors in the continuous glucose monitoring systems market. After an extended bit of patent litigation, the parties entered a 2014 settlement agreement that included a mutual covenant not to challenge each other’s patents again until 2021. DexCom at 9. 3d 1208 (Del.

Patent 64

Patent Contracts Settlement Patent Infringement 64

Patently-O

FEBRUARY 22, 2023

Patent assertion finance today is a multibillion-dollar business. [2] 2] Virtually nonexistent in the patent space in the U.S. Patent TPLF funds generally promise roughly 20% internal rates of return to funders (IRR) year-over-year, or about a 2x to 2.5x 17] At least, that’s as far as can be pieced together.

Litigation 126

Litigation Reporting Settlement Government 126